BR112015006063A2 - compostos heteroaromáticos, processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica - Google Patents

compostos heteroaromáticos, processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica

Info

Publication number
BR112015006063A2
BR112015006063A2 BR112015006063A BR112015006063A BR112015006063A2 BR 112015006063 A2 BR112015006063 A2 BR 112015006063A2 BR 112015006063 A BR112015006063 A BR 112015006063A BR 112015006063 A BR112015006063 A BR 112015006063A BR 112015006063 A2 BR112015006063 A2 BR 112015006063A2
Authority
BR
Brazil
Prior art keywords
compounds
acute
chronic pain
treatment
pharmaceutical compositions
Prior art date
Application number
BR112015006063A
Other languages
English (en)
Inventor
Lázaro Llanes García Ariel
Moraes Godinho De Oliveira Kesley
Michilini De Godoy Lidiane
De Castro Pacheco Ogari
Carlos Debom Moreira Roberto
Original Assignee
Cristalia Produtos Quim Farmaceuticos Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cristalia Produtos Quim Farmaceuticos Ltda filed Critical Cristalia Produtos Quim Farmaceuticos Ltda
Publication of BR112015006063A2 publication Critical patent/BR112015006063A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo “compostos heteroaromáticos, processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica”. a presente invenção refere-se a um composto de fórmula (i) (i) ou um sal farmaceuticamente aceitável do mesmo, com atividade analgésica. particularmente, os compostos da presente invenção são úteis para tratar ou prevenir dores aguda e crônica, em especial, dor neuropática. adicionalmente, a presente invenção fornece um processo para preparar os compostos, uma composição farmacêutica que compreende um composto de fórmula (i), e um método de tratamento para as dores agudas e crônicas. 1/1
BR112015006063A 2012-09-28 2013-09-27 compostos heteroaromáticos, processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica BR112015006063A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRBR102012024778-0A BR102012024778A2 (pt) 2012-09-28 2012-09-28 Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
PCT/BR2013/000372 WO2014047707A1 (pt) 2012-09-28 2013-09-27 Compostos heteroaromáticos, processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica

Publications (1)

Publication Number Publication Date
BR112015006063A2 true BR112015006063A2 (pt) 2017-07-04

Family

ID=50386727

Family Applications (2)

Application Number Title Priority Date Filing Date
BRBR102012024778-0A BR102012024778A2 (pt) 2012-09-28 2012-09-28 Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
BR112015006063A BR112015006063A2 (pt) 2012-09-28 2013-09-27 compostos heteroaromáticos, processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRBR102012024778-0A BR102012024778A2 (pt) 2012-09-28 2012-09-28 Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica

Country Status (4)

Country Link
US (1) US20150266864A1 (pt)
EP (1) EP2905278A4 (pt)
BR (2) BR102012024778A2 (pt)
WO (1) WO2014047707A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110938502B (zh) * 2019-12-09 2021-10-22 荆州市天翼精细化工开发有限公司 一种光学变色颜料真空镀膜基板清洗剂及其制备方法
CA3190609A1 (en) 2020-08-26 2022-03-03 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
WO2023154310A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6401404A (pt) * 1964-02-17 1965-08-18
DE2060816C3 (de) * 1970-12-10 1980-09-04 Merck Patent Gmbh, 6100 Darmstadt 4-Phenylpiperidinderivate Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen enthaltend diese Verbindungen
DE3609598A1 (de) * 1986-03-21 1987-10-01 Hoechst Ag 2-azolylmethyl-2-aryl-1,3-dioxolane und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
GB8900382D0 (en) * 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
RU2135494C1 (ru) * 1995-12-01 1999-08-27 Санкио Компани Лимитед Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина
US6133253A (en) 1996-12-10 2000-10-17 Abbott Laboratories 3-Pyridyl enantiomers and their use as analgesics
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1065205B1 (en) * 1998-03-18 2003-05-28 Taisho Pharmaceutical Co., Ltd Heteroaromatic derivatives
AU747508B2 (en) * 1998-03-19 2002-05-16 Nihon Nohyaku Co., Ltd. Arylpiperidine derivatives and use thereof
US6806275B2 (en) 2000-09-13 2004-10-19 Nihon Nohyaku Co., Ltd. Arylpiperidine derivatives and use thereof
DE10159329A1 (de) 2001-12-03 2003-06-18 Haarmann & Reimer Gmbh Verfahren zur Herstellung von beta-Ketonitrilen
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
EP1676574A3 (en) * 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
US20070001103A1 (en) 2005-07-01 2007-01-04 Labelle John Apparatus and methods for reducing noise in an optoelectronic device
TW200817375A (en) 2006-07-21 2008-04-16 Irm Llc Compounds and compositions as ITPKB inhibitors
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CA2781888C (en) * 2009-12-11 2019-06-18 Nono Inc. Agents and methods for treating ischemic and other diseases
US8742106B2 (en) 2009-12-21 2014-06-03 Novartis Ag Disubstituted heteroaryl-fused pyridines
WO2012082947A1 (en) * 2010-12-16 2012-06-21 Irm Llc Compounds and compositions as tgr5 agonists
US8877940B2 (en) * 2011-02-22 2014-11-04 Institut National De La Recherche Scientifique Antibiotic tolerance inhibitors

Also Published As

Publication number Publication date
US20150266864A1 (en) 2015-09-24
EP2905278A4 (en) 2016-11-09
BR102012024778A2 (pt) 2014-08-19
WO2014047707A1 (pt) 2014-04-03
EP2905278A1 (en) 2015-08-12

Similar Documents

Publication Publication Date Title
BR112013029692A2 (pt) derivados de imidazol úteis para o tratamento da artrite
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
WO2015031564A3 (en) Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors
BR112018010962A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratar uma infecção bacteriana, e, uso de um composto.
BR112013030894A2 (pt) moduladores do sistema imune
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112018067930A2 (pt) composto, sal de ácido trifluoroacético, composição farmacêutica, método para tratamento de uma infecção bacteriana, e, uso de um composto.
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
BR112013026834A2 (pt) composto, composição farmacêutica, produto farmacêutico de combinação, uso de um composto, e, método para tratar doenças ou condições e para inibir um bromodomínio
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
BR112013017362A2 (pt) composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores
BR112015019412A2 (pt) inibidores de bace1
BR112013001301A2 (pt) processo para preparar uma composição líquida farmacêutica compreendendo imunoglobulina g humana e composição líquida farmacêutica contendo imunoglobulina g humana
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112014029439A2 (pt) derivados de ácido salicílico, sal farmaceuticamente aceitável dos mesmos, composição dos mesmos e método de uso dos mesmos
BR112019003710A2 (pt) inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7.
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
BR112018004719A2 (pt) composto de fluoroindola, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor muscarínico m1 e uso do composto
BR112016008060A8 (pt) composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo
BR112015006063A2 (pt) compostos heteroaromáticos, processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]